Loading...
XTAEILX
Market cap224mUSD
Dec 24, Last price  
7,318.00ILS
1D
0.34%
1Q
15.81%
Jan 2017
16,773.41%
Name

Ilex Medical Ltd

Chart & Performance

D1W1MN
XTAE:ILX chart
P/E
1,609.01
P/S
87.95
EPS
4.55
Div Yield, %
0.03%
Shrs. gr., 5y
2.20%
Rev. gr., 5y
9.14%
Revenues
931m
+6.69%
461,424,000432,823,000497,495,000518,943,000553,664,000601,134,000633,958,000946,452,0001,060,994,000872,544,000930,890,000
Net income
51m
-50.17%
-22,211,00022,103,00031,105,00027,650,00037,403,00046,981,00060,257,000120,621,000197,480,000102,123,00050,885,000
CFO
80m
+15.33%
22,268,00079,814,00045,175,00012,768,00075,962,00058,601,00084,887,000182,404,000270,676,00069,739,00080,432,000
Dividend
Apr 07, 2024136.45 ILS/sh
Earnings
Jan 03, 2025

Profile

Ilex Medical Ltd engages in marketing, selling, and supporting equipment, disposables, and reagents for laboratories and healthcare establishments in Israel and South Africa. The company offers in vitro diagnostic equipment and reagent systems to hospitals, clinics, and other medical institutions; molecular biology products for cancer screening, retro virus viral load, TB, STDs, and other infectious diseases; and equipment, disposables, and reagents for in vitro fertilization, as well as food and pharma industries. It also distributes and supports nucleic acid testing blood screening solutions to large-scale blood banks; provides pre/post analytics and robotics; and develops, markets, implements, and supports laboratory information systems. In addition, the company offers specialized product range that includes molecular diagnostics, critical care, and immunology products. Ilex Medical Ltd was founded in 1977 and is based in Petah Tikva, Israel.
URL
https://www.ilexmedical.com/
IPO date
Jan 01, 1995
Employees
255
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
930,890
6.69%
872,544
-17.76%
1,060,994
12.10%
Cost of revenue
731,161
622,274
708,826
Unusual Expense (Income)
NOPBT
199,729
250,270
352,168
NOPBT Margin
21.46%
28.68%
33.19%
Operating Taxes
18,518
34,618
57,866
Tax Rate
9.27%
13.83%
16.43%
NOPAT
181,211
215,652
294,302
Net income
50,885
-50.17%
102,123
-48.29%
197,480
63.72%
Dividends
(21,442)
(60,000)
(59,997)
Dividend yield
3.26%
5.55%
327.09%
Proceeds from repurchase of equity
(5,716)
(3,487)
BB yield
0.87%
0.32%
Debt
Debt current
11,880
12,839
13,094
Long-term debt
83,925
88,979
101,964
Deferred revenue
18,390
7,016
Other long-term liabilities
77,681
Net debt
(175,413)
(171,801)
(176,271)
Cash flow
Cash from operating activities
80,432
69,739
270,676
CAPEX
(48,771)
(28,359)
(42,641)
Cash from investing activities
(90,677)
(53,636)
(82,451)
Cash from financing activities
(40,718)
(77,298)
(86,781)
FCF
176,237
149,104
296,198
Balance
Cash
213,264
224,199
282,941
Long term investments
57,954
49,420
8,388
Excess cash
224,674
229,992
238,279
Stockholders' equity
482,213
527,888
484,869
Invested Capital
524,778
450,835
362,653
ROIC
37.15%
53.02%
77.55%
ROCE
26.65%
36.59%
57.96%
EV
Common stock shares outstanding
11,190
11,279
11,281
Price
58.80
-38.63%
95.82
5,792.99%
1.63
32.20%
Market cap
657,972
-39.12%
1,080,754
5,791.94%
18,343
39.77%
EV
482,559
970,746
(98,134)
EBITDA
247,453
300,309
402,659
EV/EBITDA
1.95
3.23
Interest
2,655
1,607
2,012
Interest/NOPBT
1.33%
0.64%
0.57%